The Relationship Between the Modulation of Intestinal Microbiota and the Response to Immunotherapy in Patients with Cancer
Open Access
- 3 January 2025
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 96
Abstract
The intestinal microbiota is an important part of the human body, and its composition can affect the effectiveness of immunotherapy. In the last few years, the modulation of intestinal microbiota in order to improve the effectiveness of immunotherapy has become a current topic in the scientific community, but there is a lack of research in this area. In this review, the goal was to analyze the current relevant literature related to the modulation of intestinal microbiota and the effectiveness of immunotherapy in the treatment of cancer. The effects of antibiotics, probiotics, diet, and fecal microbial transplantation were analyzed separately. It was concluded that the use of antibiotics, especially broad-spectrum types or larger quantities, causes dysbiosis of the intestinal microbiota, which can reduce the effectiveness of immunotherapy. While dysbiosis could be repaired by probiotics and thus improve the effectiveness of immunotherapy, the use of commercial probiotics without evidence of intestinal dysbiosis has not yet been sufficiently tested to confirm its safety for cancer for immunotherapy-treated cancer patients. A diet consisting of sufficient amounts of fiber, as well as a diet with higher salt content positively correlates with the success of immunotherapy. Fecal transplantation is a safe and realistic adjuvant option for the treatment of cancer patients with immunotherapy, but more clinical trials are necessary. Modulating the microbiota composition indeed changes the effectiveness of immunotherapy, but in the future, more human studies should be organized to precisely determine the types and procedures of microbiota modulation.Keywords
This publication has 46 references indexed in Scilit:
- 1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)Annals of Oncology, 2024
- Impact of antibiotics on the human microbiome and consequences for host healthMicrobiologyopen, 2022
- Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeuticsApplied Microbiology and Biotechnology, 2022
- Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironmentCell, 2021
- Clinical impact of probiotics on the efficacy of anti‐PD‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weightingInternational Journal of Cancer, 2021
- Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer TumorsJAMA Network Open, 2020
- Cancer immunotherapy: Pros, cons and beyondBiomedicine & Pharmacotherapy, 2020
- Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancerClinical and Translational Oncology, 2020
- Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With CancerJAMA Oncology, 2019
- An insight into gut microbiota and its functionalitiesCellular and Molecular Life Sciences, 2018